Next NX232-107-158-006 to#3 milestone 3 (BASE) - PK & bioavail stud W/selected anticancer compaounds in mice, PK & pharm evals of agents being developed for cancer patients, HHSN261201600024I,…
Ended Awarded Last action
- Contract number
- HHSN26100003
- Awardee
-
Mayo Clinic UEI Y2K4F9RPRRG7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $167,150
Award facts
- Opportunity
-
- N02CM6700011 Solicitation number
- Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients Award Notice · Posted Feb 22, 2016
- Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients Award Notice · Posted Feb 5, 2016
- Preclinical Pharmacokinetic and Pharmacological Studies Being Developed for Cancer Patients Award Notice · Posted Oct 6, 2015
- Contract value 100% obligated
- $167,149.99 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Rochester, MN 55905, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$0 | |
| Exercise an Option | $100,290 | |
| Exercise an Option | $16,715 | |
| Exercise an Option | $33,430 | |
| Original award | $16,715 |
About this award
The National Cancer Institute issued a $167,149.99 delivery order to Mayo Clinic on August 7, 2017, under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients parent IDIQ for pharmacokinetic and bioavailability studies of selected anticancer compounds in mice and pharmacological evaluations of agents in development for cancer patients.
Place of performance is Rochester, Minnesota. The order's ultimate completion date is June 30, 2021. Pricing is cost with no fee. Performance through fiscal year 2021 comprised 16 contractor hours invoiced at a derived rate of $54.61 per hour, with no subcontractor involvement; Mayo Clinic self-performed all work.
Description
Next NX232-107-158-006 to#3 milestone 3 (BASE) - PK & bioavail stud W/selected anticancer compaounds in mice, PK & pharm evals of agents being developed for cancer patients, HHSN261201600024I, DTP-17-035 TPB 8/4/2017 - 6/30/2021
Quick answers
Who was awarded contract HHSN26100003?
HHSN26100003 was awarded to Mayo Clinic by National Cancer Institute (National Institutes of Health) on August 7, 2017.
How much is contract HHSN26100003 worth?
The government has obligated $167,150 on HHSN26100003.
Is contract HHSN26100003 an order under another contract?
Yes. HHSN26100003 is a delivery order under HHSN261201600024I, an indefinite delivery contract, on Pharmacokinetic and Pharmacology Evaluations for Cancer Patients.
Was contract HHSN26100003 competed?
The extent of competition for HHSN26100003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award